Satori Pharma doesn’t forget to raise $7M for Alzeimers

Posted on 21. Jan, 2011 by in News

The Boston Business Journal reported:

Satori Pharmaceuticals, a biotechnology company targeting hard to treat neurodegenerative diseases, including Alzeimerā€™s, has raised $7 million out of a planned fundraise of $20 million. The company previously raised a series A round worth $22 million in January of 2009, following a $3 million seed funding round.

The Cambridge, Mass.-based Satori, whose name is Japanese for understanding or enlightenment, includes board members from venture firms PureTech Ventures, based in Boston, Palo Alto, Cal-based Prospect Ventures, InterWest Partners, with offices in Palo Alto, Cal. and Dallas, Tex., and New Enterprise Associates, with U.S. offices in Cal. and Maryland. All four venture firms contributed to the Series A funding. The company did not disclose in regulatory documents which firms participated in this most recent financing.

No comments.

Leave a Reply